Inhibition of proliferation of prostate cancer cells by a 19-nor- hexafluoride vitamin D3 analogue involves the induction of p21(waf1) p27(kip1) and E-cadherin

Journal of Molecular Endocrinology

Volumn 19, Issue 1, 1997, Pages 15-27

  Campbell, M J ^a,c   Elstner, E ^a   Holden, S ^a   Uskokovic, M ^b   Koeffler, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; PROTEIN P21; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CLONAL ANERGY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR UPREGULATION; REMISSION; TUMOR SUPPRESSOR GENE;

EID: 0030737494     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0190015     Document Type: Article

References (60)

1. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochemical Pharmacology 42 1569-1575.
2. Bouillon R, Okamura WH & Norman AW 1995 Structure-function relationships in the vitamin D endocrine system. Endocrinology Reviews 16 200-257.
3. Brenner RV, Shabahang M, Schumaker LM, Nauta RJ, Uskokovic MR, Evans SR & Buras RR 1995 The antiproliferative effect of vitamin D analogues on MCF-7 human breast cancer cells. Cancer Letters 92 77-82.
4. Carrol AG, Voeller HJ, Sugars L & Gelmann EP 1993 p53 oncogene mutations in three prostate cancer cell lines. Prostate 23 123-134.
5. 3. Molecular Endocrinology 9 1814-1824.
6. Cheng L, Nagabhushan M, Pretlow TP, Amini SB & Pretlow TG 1996 Expression of E-cadherin in primary and metastatic prostate. Modern Pathology 148 1375-1380.
7. Danesi R, Figg WD, Reed E & Myers CE 1995 Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Molecular Pharmacology 47 1106-1111.
8. 3 is due to reduced catabolism and altered protein binding. Biochemical Pharmacology 47 987-993.
9. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 84 1960-1967.
10. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Research 55 2822-2830.
11. Fero ML, Rivkin M, Tasch M, Porter P, Carow C, Firpo E, Polyak K, Tsai L, Broudy V, Perlmutter R, Kaushansky K & Roberts JM 1996 A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 deficient mice. Cell 85 733-744.
12. Gaddipati JP, Mcleod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW & Srivastva S 1994 Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Research 54 2861-2864.
13. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW & Srivastava S 1995 Alteration of the tumor suppressor gene p53 in a high fraction of hormone refactory prostate cancer. Journal of Urology 154 414-421.
14. Hengst L & Reed S 1996 Translational control of p27 accumulation during the cell cycle. Science 271 1861-1863.
15. Honda A, Nakashima N, Mori Y, Katsumata T & Ishizuka S 1992 Effects of vitamin D-binding proteins on HL-60 cell differentiation induced by 26,26,26,27,27,27-hexafluoro-1 alpha,25-dihydroxyvitamin D. Journal of Steroid Biochemistry and Molecular Biology 41 109-112.
16. Hsieh TC, Xu W & Chiao JW 1995 Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Experimental Cell Research 218 137-143.
17. 3 response element. Leukemia Research 19 147-158.
18. 3. Biochemical Pharmacology 45 2331-2336.
19. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD & Ewing CM 1994 Genetic alterations in prostate cancer. Cold Spring Harbor Symposia on Quantitative Biology 59 653-659.
20. 3. Biochemical Pharmacology 41 1601-1606.
21. Li CJ, Wang C & Pardee AB 1995 Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Research 55 3712-3715.
22. Li X & Daryzynkiewicz Z 1995 Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Proliferation 28 571-579.
23. Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR & Samid D 1994 Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. Journal of Investigative Dermatology 103 335-340.
24. Liu M, Lee M, Cohen M, Bommakanti M & Freedman L 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U-937. Genes and Development 10 142-153.
25. 3 in seven human prostatic carcinoma cell lines. Clinical Cancer Research 1 997-1003
26. 3 responsive element and glucocorticoid repression in the osteocalcin gene. Science 246 1158-1161.
27. Munker R, Norman A & Koeffler HP 1986 Vitamin D compounds. Journal of Clinical Investigation 78 424-430.
28. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M & Koeffler HP 1996 A new series of vitamin D analogues is highly active for clonal inhibition, differentiation and induction of WAF1 in myeloid leukaemia. Blood 88 2201-2209.
29. 3: towards an endocrine therapy of brain tumours? Journal of Neurological Research 37 271-277.
30. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Research 50 6857-6864.
31. Novichenko N, Konno S, Nakajima V, Hsieh TC, Xu W, Turo K, Ahmed T & Chiao JW 1995 Growth attenuation in a human prostate cell line mediated by a phorbol ester. Proceedings of the Society of Experimental Biology and Medicine 209 152-156.
32. Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M & Rubben H 1993 E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urological Research 21 359-362.
33. Ozono K, Liao J, Kerner S, Cott R & Pike JW 1990 The vitamin D-responsive element in the human osteocalcin gene. Journal of Biological Chemistry 265 21881-21888.
34. 3 analogues: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leukemia Research 19 65-72.
35. Paquette RL & Koeffler HP 1992 Differentiation therapy. Hematology/Oncology Clinic of North America 6 687-706.
36. Parker SB, Eichele G, Zhang P, Rawis A, Sands AT, Bradely A, Olson EN, Harper JW & Elledge SJ 1995 p53-Independent expression of p21 in muscle and other terminally differentiating cells. Science 267 1024-1027.
37. Parker SL, Tong T, Bolden S & Wingo PA 1996 Cancer Statistics. CA: A Cancer Journal for Clinicians 65 5-27.
38. 3 on primary cultures of human prostatic cells. Cancer Research 54 805-810.
39. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G & Boothman A 1995 Beta-lapachone-mediated apoptosis in human promyelocytic leukaemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Research 55 3706-3711.
40. 3, a novel bioactive metabolite. In 9th Workshop on Vitamin D, p 210. Eds R Bouillon, AW Norman & M Thomasset. Orlando, Florida.
41. Samid D, Shack S & Myers CE 1993 Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. Journal of Clinical Investigation 91 2288-2295.
42. Sasaki H, Harada H, Handa Y, Morino H, Suzawa M, Shimpo E, Katsumata T, Mashhiro Y, Matsuda K, Ebihara K, Ono T, Masushige S & Kato S 1995 Transcriptional activity of a fluorinated Vitamin D analogue on VDR-RXR mediated gene expression. Biochemistry 34 370-377.
43. Schwaller J, Koeffler HP, Nicklaus G, Loetscher P, Nagel S, Fey MF & Tobler A 1993 Posttranscriptional stabilization underlies p53-independent induction of p21 in differentiating human leukemic cells. Journal of Clinical Investigation 95 973-979.
44. Schwartz GG, Oeler TA, Uskokovic MR & Bahnson RR 1994 Human prostate cancer cells: inhibition of proliferation by vitamin D analogues. Anticancer Research 14 1077-1081.
45. 3 and prostate cancer cell proliferation in vivo. Journal of Urology 46 365-369.
46. 3. Cancer Research 54 4057-4064.
47. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132 1952-1960.
48. 3. Endocrinology 136 20-26.
49. Steinman RA, Hoffman B, Iro A, Guillouf C, Lieberman D & ell-Houseini ME 1994 Induction of p21(waf1/cip1) during differentiation. Oncogene 9 3389-3396.
50. Su L, Vogelstein B & Kinzler K 1993 Association of the APC tumour suppressor protein with catenins. Science 262 1734-1737.
51. Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FM & Schalken JA 1996 p16 mutations/deletions are not frequent events in prostate cancer. British Journal of Cancer 74 120-122.
52. Umbas R, Schalken JA, Alders TW, Carter BS, Kathaus HFM, Schaafsma HE, Debruyne FMJ & Isaacs WB 1992 Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Research 52 5104-5109.
53. Umbas R, Isacs WB, Bringuier PP, Scaahsma HA, Kathaus HF, Oosterhof GO, Debruyne FM & Schalken JA 1994 Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Research 54 3929-3933.
54. 3, inhibits azoxymethane-induced colonic tumourigenesis. Cancer Research 55 3050-3054.
55. Wang J & Walsh K 1996 Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273 359-361.
56. 3 in HL60 cells. Cancer Research 56 264-267.
57. Welsh J 1994 Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochemical and Cell Biology 72 537-545.
58. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AN & Mercer WE 1995 p53-independent induction of WAF1/CIP1 in human leukaemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Research 55 668-674.
59. 3 prolongs survival time of leukemic mice. Proceedings of the National Academy of Sciences of the USA 87 3929-3932.
60. 3 analogue with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 78 75-82.